|
Dan Kisner has a long history of leading venture-backed companies. Most recently, Dan served as President and CEO of Caliper Technologies. Dan led Caliper, a leader in microfluidic lab-on-a-chip technology, from a technology-focused start up to a publicly traded, commercially oriented organization. Prior to Caliper, he was the President and COO of Isis Pharmaceuticals, Inc.
Previously, Dan was Division VP of Pharmaceutical Development for Abbott Laboratories and VP of Clinical Research and Development at SmithKline Beckman Pharmaceuticals. In addition, he held a tenured position in the Division of Oncology at the University of Texas, San Antonio School of Medicine and is certified by the American Board of Internal Medicine in Internal Medicine and Medical Oncology.
Since joining Aberdare, Dan has been involved in assessing and analyzing progress across all of the biopharma portfolio. Additionally, he played a key role in new investment decisions with Idun, Avera Pharmaceuticals (where Dan is Chairman), Mpex Pharmaceuticals, Ruxton Pharmaceuticals, Salmedix and Sequoia.
In addition to his responsibilities at Aberdare, Dan serves as Chairman of Caliper's Board and he is also on the boards of several private companies. He holds a BA from Rutgers University and an MD from Georgetown University. | 